Evercore ISI raised the firm’s price target on Insmed to $75 from $42 and keeps an Outperform rating on the shares. The firm sees a 75% probability of success for brensocatib in bronchiectasis, up from 30%, post-data, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: